{"id":24983,"date":"2025-03-14T15:46:41","date_gmt":"2025-03-14T15:46:41","guid":{"rendered":"https:\/\/news.godj.com\/news\/men-denied-life-extending-prostate-cancer-drug-on-nhs-in-england\/"},"modified":"2025-03-14T15:46:41","modified_gmt":"2025-03-14T15:46:41","slug":"men-denied-life-extending-prostate-cancer-drug-on-nhs-in-england","status":"publish","type":"post","link":"https:\/\/news.godj.com\/news\/men-denied-life-extending-prostate-cancer-drug-on-nhs-in-england\/","title":{"rendered":"Men denied life-extending prostate cancer drug on NHS in England"},"content":{"rendered":"


\n<\/p>\n

\n
\n
\n
\n
\n
Hugh Pym and Ian Atkinson<\/span><\/p>\n

BBC News<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\"InstituteInstitute of Cancer Research<\/span><\/div>\n<\/div>\n

Abiraterone tablets can help stop prostate cancer spreading<\/figcaption><\/p>\n<\/figure>\n
\n

A cancer charity has said it is “angry and frustrated” that ministers and health officials have not approved the provision of a life-extending prostate cancer drug through the NHS in England.<\/p>\n

The drug, abiraterone, has been available in Scotland and Wales for two years for high-risk patients whose cancer has not yet spread, but not in England and Northern Ireland.<\/p>\n

In a letter to Prostate Cancer UK, seen by the BBC, Health Minister Karin Smyth said the decision by NHS England, following a lengthy review, was “based on overall affordability” and that “it would not be appropriate to intervene”. <\/p>\n

The government said urgent advice had been requested on the issue.<\/p>\n<\/div>\n

\n

The charity said it was a “dire and urgent situation in England” with “a bureaucratic blockage denying men this treatment”.<\/p>\n

A Department of Health and Social Care spokesperson said: “We understand the frustration and upset of some patients who cannot access this potentially life-saving treatment. Ministers have requested urgent advice on the issue.”<\/p>\n

Although not a cure, abiraterone can help stop prostate cancer spreading to other parts of the body. <\/p>\n

In England and Northern Ireland, the drug is only approved for men with very advanced prostate cancer which has spread already. <\/p>\n

In Wales and Scotland, people with the disease that has not yet spread can also get it.<\/p>\n

Research has shown that for these earlier stage patients, the survival rate after six years is improved and that the drug halved the rate of progression of the cancer.<\/p>\n<\/div>\n

\n
\n
\"GilesGiles Turner<\/span><\/div>\n<\/div>\n<\/figure>\n
\n

The charity says many lives could be extended by the drug, given the findings from a trial called Stampede, published in 2022.<\/a> <\/p>\n

It found improved odds of survival among men given the drug alongside usual care, and concluded that abiraterone should be considered a new standard treatment. <\/p>\n

According to figures from NHS England, each year about 8,400 patients have high-risk prostate cancer that has not yet spread. <\/p>\n

Using the Stampede assumptions, 672 of those men could die prematurely without access to abiraterone.<\/p>\n<\/div>\n

\n

In October 2023,<\/a> BBC News spoke to Giles Turner, a retired banker living in Sussex. He was diagnosed with prostate cancer earlier that year but was told that abiraterone could not be obtained on the NHS in England. <\/p>\n

He chose to pay for treatment with the drug at \u00a3250 a month. He told us then that he felt “very fortunate” to be able to afford it, but outraged for others who could not. <\/p>\n

At the time, NHS England said it was reviewing the drug’s use for a wider range of men. <\/p>\n

However, in December 2024 it told Prostate Cancer UK that “it has not been possible to identify the necessary recurrent headroom in revenue budgets”. <\/p>\n

Because abiraterone is a generic drug which has gone “off patent” and is licensed for only one group of prostate cancer patients, there is a complicated process to get it approved for wider use.<\/p>\n

Each year, NHS England can make “discretionary” investment decisions with a specialist advisory group, but it has chosen not to for this drug. <\/p>\n

Smyth’s letter earlier this month said the process had to look at “the overall budget impact of introducing a new treatment based on patient volumes”, and ministers would not intervene.<\/p>\n

Mr Turner said he was “stunned” that nearly one-and-a-half years after the BBC report, NHS England had not caught up with NHS Scotland and NHS Wales. <\/p>\n

He has spent \u00a320,000 so far on his treatment, and said he felt it was wrong that while expensive new patented drugs treatments could be funded, abiraterone – costing the NHS \u00a377 per pack per month – could not be. <\/p>\n<\/div>\n<\/div>\n


\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Hugh Pym and Ian Atkinson BBC News Institute of Cancer Research Abiraterone tablets can help stop prostate cancer spreading A cancer charity has said it is “angry and frustrated” that ministers and health officials have not approved the provision of a life-extending prostate cancer drug through the NHS in England. The drug, abiraterone, has been […]<\/p>\n","protected":false},"author":1,"featured_media":24984,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[64],"tags":[896,2593,2988,278,6210,691,144,1851],"class_list":["post-24983","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-cancer","tag-denied","tag-drug","tag-england","tag-lifeextending","tag-men","tag-nhs","tag-prostate"],"_links":{"self":[{"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/posts\/24983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/comments?post=24983"}],"version-history":[{"count":1,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/posts\/24983\/revisions"}],"predecessor-version":[{"id":24985,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/posts\/24983\/revisions\/24985"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/media\/24984"}],"wp:attachment":[{"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/media?parent=24983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/categories?post=24983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/tags?post=24983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}